News

The recent reports have demonstrated PD-L1 to be up-regulated on the surface of tumor cells, implicating this protein as one of the factors that allows tumors to evade

The company has designed GENASSIST to make genome editing accessible for everyone. Horizon offers not just plasmids for CRISPR gene editing, but also custom guide RNA design and

With the three-year agreement, the company now enters into the growing Canadian OTC drug market, which was valued at more than $3.1bn in 2012. Jestaw has over 14

The boards of directors of Sun Pharma, Ranbaxy, and Daiichi Sankyo, which is Ranbaxy’s controlling shareholder, have unanimously approved the proposed transaction. Ranbaxy’s board and Sun Pharma’s board

Cedarburg, whose capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active pharmaceutical ingredients (API’s) for both generic and branded

The FDA action date (PDUFA date) for Fibrocaps is 31 January 2015. In August 2013, The Medicines Company announced that the Phase III trial, FINISH-3, which studied a

Otezla is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). Otezla was approved by the FDA on 21 March 2014, and is

Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Eisai will partner with Abela Frères to market eribulin in

Emapticap pegol is a Spiegelmer that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in diabetic kidney